Literature DB >> 10720514

CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1.

J Reynes1, P Portales, M Segondy, V Baillat, P André, B Réant, O Avinens, G Couderc, M Benkirane, J Clot, J F Eliaou, P Corbeau.   

Abstract

The intensity of expression of the chemokine receptor CCR5 is involved in in vitro cell infectability by human immunodeficiency virus (HIV)-1 R5 isolates. Because CCR5 expression varies among individuals, the hypothesis that this expression could determine virus load in HIV-1-infected persons was tested. The mean number of CCR5 molecules per cell was measured on peripheral blood CD4+ T lymphocytes (CCR5 density) from HIV-1-infected, asymptomatic, nontreated adults. There was a strong correlation between HIV RNA plasma level and CCR5 density (P=.009) that was independent of cell activation and was not due to an HIV-induced CCR5 up-regulation. These data are compatible with the hypothesis that CCR5 density is a key factor governing cell infectability and in vivo virus production and explain the protective effect of the Delta32CCR5 deletion, which results in low CCR5 expression. CCR5 density might be of critical predictive value in HIV infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720514     DOI: 10.1086/315315

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  74 in total

1.  Duration of sample storage dramatically alters expression of the human immunodeficiency virus coreceptors CXCR4 and CCR5.

Authors:  S Shalekoff; C T Tiemessen
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Expression and functional activity of CXCR-4 and CCR-5 chemokine receptors in human thymocytes.

Authors:  R Zamarchi; P Allavena; A Borsetti; L Stievano; V Tosello; N Marcato; G Esposito; V Roni; C Paganin; G Bianchi; F Titti; P Verani; G Gerosa; A Amadori
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

3.  CCR5 deficiency mitigates the deleterious effects of tumor necrosis factor α antagonism in murine histoplasmosis.

Authors:  Danielle N Kroetz; George S Deepe
Journal:  J Infect Dis       Date:  2012-01-23       Impact factor: 5.226

4.  The effects of early syphilis on CD4 counts and HIV-1 RNA viral loads in blood and semen.

Authors:  S T Sadiq; J McSorley; A J Copas; J Bennett; S J Edwards; S Kaye; S Kirk; P French; I V D Weller
Journal:  Sex Transm Infect       Date:  2005-10       Impact factor: 3.519

5.  The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density.

Authors:  Caroline Desmetz; Yea-Lih Lin; Clément Mettling; Pierre Portalès; Herisoa Rabesandratana; Jacques Clot; Pierre Corbeau
Journal:  Immunology       Date:  2006-12       Impact factor: 7.397

6.  Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody.

Authors:  Pierre Portalès; Sylvie Fabre; Thierry Vincent; Caroline Desmetz; Brigitte Réant; Danièle Noël; Jacques Clot; Christian Jorgensen; Pierre Corbeau
Journal:  Immunology       Date:  2009-03-26       Impact factor: 7.397

7.  Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques.

Authors:  Yin Xu; Chris Weatherall; Michelle Bailey; Sheilajen Alcantara; Robert De Rose; Jerome Estaquier; Kim Wilson; Kazuo Suzuki; Jacques Corbeil; David A Cooper; Stephen J Kent; Anthony D Kelleher; John Zaunders
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin.

Authors:  F Nicoletti; C Lapenta; C Lamenta; S Donati; M Spada; A Ranazzi; B Cacopardo; K Mangano; F Belardelli; C Perno; S Aquaro
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

9.  Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Authors:  Alonso Heredia; Olga Latinovic; Robert C Gallo; Gregory Melikyan; Marv Reitz; Nhut Le; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

10.  Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative.

Authors:  Elizabeth M Stringer; Mark Giganti; Rosalind J Carter; Wafaa El-Sadr; Elaine J Abrams; Jeffrey Sa Stringer
Journal:  AIDS       Date:  2009-11       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.